Royalty Pharma Plc is a biotechnology business based in the US. Royalty Pharma Plc shares (RPRX) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $41.26 |
|---|---|
| 52-week range | $34.25 - $44.65 |
| 50-day moving average | $42.92 |
| 200-day moving average | $40.85 |
| Wall St. target price | $54.34 |
| PE ratio | 39.1553 |
| Dividend yield | $0.72 (1.85%) |
| Earnings per share (TTM) | $1.03 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $41.26 from 2022-09-28
| 1 week (2022-09-22) | 0.49% |
|---|---|
| 1 month (2022-08-30) | -1.41% |
| 3 months (2022-06-30) | -1.86% |
| 6 months (2022-03-30) | 5.79% |
| 1 year (2021-09-30) | 14.17% |
|---|---|
| 2 years (2020-09-30) | -1.93% |
| 3 years (2019-09-26) | N/A |
| 5 years (2017-09-26) | N/A |
Valuing Royalty Pharma Plc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Royalty Pharma Plc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Royalty Pharma Plc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, Royalty Pharma Plc shares trade at around 39x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Royalty Pharma Plc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Royalty Pharma Plc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Royalty Pharma Plc's overall financial performance and is widely used to measure a its profitability.
To put Royalty Pharma Plc's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $2.3 billion |
|---|---|
| Operating margin TTM | 46.65% |
| Gross profit TTM | $1.8 billion |
| Return on assets TTM | 3.85% |
| Return on equity TTM | 8.6% |
| Profit margin | 20.63% |
| Book value | $13.79 |
| Market capitalisation | $27.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 25.34% of net profits
Recently Royalty Pharma Plc has paid out, on average, around 25.34% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.85% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Royalty Pharma Plc shareholders could enjoy a 1.85% return on their shares, in the form of dividend payments. In Royalty Pharma Plc's case, that would currently equate to about $0.72 per share.
While Royalty Pharma Plc's payout ratio might seem fairly standard, it's worth remembering that Royalty Pharma Plc may be investing much of the rest of its net profits in future growth.
Royalty Pharma Plc's most recent dividend payout was on 15 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 18 August 2022 (the "ex-dividend date").
Royalty Pharma Plc's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Over the last 12 months, Royalty Pharma Plc's shares have ranged in value from as little as $34.2492 up to $44.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Royalty Pharma Plc's is 0.302. This would suggest that Royalty Pharma Plc's shares are less volatile than average (for this exchange).
To put Royalty Pharma Plc's beta into context you can compare it against those of similar companies.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
